Someone with a lot of money to spend has taken a bearish stance on Teva Pharmaceutical Indus TEVA.
And retail traders should know.
We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.
Whether this is an institution or just a wealthy individual, we don't know. But when something this big happens with TEVA, it often means somebody knows something is about to happen.
So how do we know what this whale just did?
Today, Benzinga's options scanner spotted 28 uncommon options trades for Teva Pharmaceutical Indus.
This isn't normal.
The overall sentiment of these big-money traders is split between 28% bullish and 71%, bearish.
Out of all of the special options we uncovered, 24 are puts, for a total amount of $1,874,669, and 4 are calls, for a total amount of $215,920.
What's The Price Target?
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $5.0 to $10.0 for Teva Pharmaceutical Indus over the last 3 months.
Volume & Open Interest Development
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Teva Pharmaceutical Indus's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Teva Pharmaceutical Indus's whale trades within a strike price range from $5.0 to $10.0 in the last 30 days.
Teva Pharmaceutical Indus Option Volume And Open Interest Over Last 30 Days
Biggest Options Spotted:
|Symbol||PUT/CALL||Trade Type||Sentiment||Exp. Date||Strike Price||Total Trade Price||Open Interest||Volume|
Where Is Teva Pharmaceutical Indus Standing Right Now?
- With a volume of 8,110,928, the price of TEVA is up 4.99% at $8.73.
- RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.
- Next earnings are expected to be released in 61 days.
What The Experts Say On Teva Pharmaceutical Indus:
- Piper Sandler has decided to maintain their Underweight rating on Teva Pharmaceutical Indus, which currently sits at a price target of $7.
- JP Morgan downgraded its action to Underweight with a price target of $10
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Teva Pharmaceutical Indus, Benzinga Pro gives you real-time options trades alerts.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.